- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00405418
Lantus Versus Levemir Treat-To-Target (L2T3)
Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir.
Primary objective:
To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment period and do not experience symptomatic hypoglycemia, confirmed by plasma glucose (PG) ≤ 56 mg/dL (3.1 mmol/L)
Secondary objectives:
- To compare between the 2 treatment groups, the percentage of patients who reach the target of HbA1c < 7% and < 6.5% at the end of the treatment period
- To compare the changes in HbA1c and fasting plasma glucose (FPG)
- To compare the evolution of blood glucose profiles
- To compare the day to day FPG variability, the insulin doses
- To determine in each treatment group the biochemical and patient-related determinants of failure to reach HbA1c targets
- To compare the overall incidence and rate of symptomatic hypoglycemia and nocturnal symptomatic hypoglycemia confirmed by PG ≤ 56 mg/dL (3.1 mmol/L)
- To compare over the treatment period, the overall incidence and rate of symptomatic hypoglycemia and symptomatic nocturnal hypoglycemia (with PG ≤ 70 mg/dL [3.9 mmol/L]), of symptomatic day-time hypoglycemia (with PG ≤ 70 mg/dL and with PG ≤ 56 mg/dL), of severe hypoglycemia, of asymptomatic hypoglycemia with PG ≤ 56 mg/dL
- To compare the overall safety: incidence of adverse events (including serious hypoglycemia and local tolerance at injection site), change in body weight, in waist circumference and in waist / hip ratio
- To assess the quality of life and treatment satisfaction
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
-
North Ryde, Australia
- Sanofi-Aventis
-
-
-
-
-
Sao Paolo, Brasile
- Sanofi-Aventis
-
-
-
-
-
Laval, Canada
- Sanofi-Aventis
-
-
-
-
-
Seoul, Corea, Repubblica di
- Sanofi-Aventis
-
-
-
-
-
Hoersholm, Danimarca
- Sanofi-Aventis
-
-
-
-
-
Moscow, Federazione Russa
- Sanofi-Aventis
-
-
-
-
-
Helsinki, Finlandia
- Sanofi-Aventis
-
-
-
-
-
Berlin, Germania
- Sanofi-Aventis
-
-
-
-
-
Mumbai, India
- Sanofi-Aventis
-
-
-
-
-
Dublin, Irlanda
- Sanofi-Aventis
-
-
-
-
-
Gouda, Olanda
- Sanofi-Aventis
-
-
-
-
-
Porto Salvo, Portogallo
- Sanofi-Aventis
-
-
-
-
-
Guildford, Regno Unito
- Sanofi-Aventis
-
-
-
-
-
Bucharest, Romania
- Sanofi-Aventis
-
-
-
-
-
Belgrade, Serbia
- Sanofi-Aventis
-
-
-
-
-
Barcelona, Spagna
- Sanofi-Aventis
-
-
-
-
-
Stockholm, Svezia
- Sanofi-Aventis
-
-
-
-
-
Meyrin, Svizzera
- Sanofi-Aventis
-
-
-
-
-
Istanbul, Tacchino
- Sanofi-Aventis
-
-
-
-
-
Taipe, Taiwan
- Sanofi-Aventis
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Type 2 diabetes for at least 1 year
- Insulin naïve
- Treated with stable doses of oral antidiabetics for at least 3 months prior to study start, including at least metformin (at least 1g/day)
- 7% ≤ HbA1c ≤ 10.5 %
- Body mass index (BMI) < 40 kg/m²
- Ability and willingness to perform blood glucose monitoring using a blood glucose meter and to use a patient diary
Exclusion Criteria:
- Type 1 diabetes
- Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for less than 1 week)
- Treatment with glucagon-like peptide (GLP)-1 receptor agonists or with dipeptidyl peptidase (DPP)-IV inhibitors
- Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)
- Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method)
- Breast-feeding
- History of hypersensitivity to the study drugs or to drugs with a similar chemical structure
- Treatment with systemic corticosteroids in the 3 months prior to study entry
- Treatment with any investigational product in the 2 months prior to study entry
- Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
- Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
- Impaired hepatic function as shown by Alamine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal range at study entry
- Impaired renal function as shown by serum creatinine ≥ 1.5 mg/dL (≥ 133 μmol/L) in men and ≥ 1.4 mg/dL (124 μmol/L) in women at study entry
- History of drug or alcohol abuse in the last year
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: 1
Insulin Glargine
|
Subcutaneous injection, once a day in the evening
|
|
Comparatore attivo: 2
Insulin Detemir
|
Subcutaneous injection, twice a day at breakfast and before dinner
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
HbA1c recorded
Lasso di tempo: At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
|
Self-monitored fasting BG in both treatment arms and pre-dinner BG in detemir arm
Lasso di tempo: On the 4 consecutive days before each visit
|
On the 4 consecutive days before each visit
|
|
Self-monitored BG values from 8-point 24-hour profile recorded on 2 consecutive days
Lasso di tempo: Within the week prior to baseline, week 12 and week 24
|
Within the week prior to baseline, week 12 and week 24
|
|
Episodes of hypoglycemia (symptomatic, total and categorized as day-time/nocturnal, severe or asymptomatic)
Lasso di tempo: All across the study
|
All across the study
|
|
Self-monitored BG values whenever patient experiences symptoms possibly related to hypoglycemia.
Lasso di tempo: All across the study
|
All across the study
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Doses of insulin glargine or insulin detemir
Lasso di tempo: Daily
|
Daily
|
|
Laboratory fasting plasma glucose
Lasso di tempo: At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
|
Insulinemia and fasting C-peptide level
Lasso di tempo: At baseline
|
At baseline
|
|
Lipid profile
Lasso di tempo: at baseline and week 24
|
at baseline and week 24
|
|
Patient reported outcomes (quality of life and treatment satisfaction)
Lasso di tempo: at baseline, week 4, week 12 and at the last visit
|
at baseline, week 4, week 12 and at the last visit
|
|
Safety data: occurrence of adverse events and weight
Lasso di tempo: assessed at each visit
|
assessed at each visit
|
|
Waist and hip circumferences
Lasso di tempo: measured at baseline, week 12 and week 24
|
measured at baseline, week 12 and week 24
|
|
Systolic and diastolic blood pressure
Lasso di tempo: measured at study entry, baseline, week 12 and week 24
|
measured at study entry, baseline, week 12 and week 24
|
|
Physical examination
Lasso di tempo: performed at study entry and at last visit.
|
performed at study entry and at last visit.
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Valérie Pilorget, Sanofi
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- LANTU_C_00579
- EUDRACT # : 2006-000324-13
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .